Thanks Chris.
activity regarding of and CAR-TXpress with As was selection the benefits release the engaging increased platform. quarter cell and research for highlight the our academia key of during the Chris our X-Mini mentioned, second our industry kit market, the
X-series exhibited in time for International We in the May products of our Society Therapy first Cell the also Montreal. at
response and During publications the demonstrating early several The the year. of technology ISCT, our more have we presented highly in direct and is remainder positive and this during of just generate also X-Wash starting occurs for and X-BACS very have a abstracts force. to is value conferences upcoming feedback planned received aggressive we sales especially given additional been also abstracts outreach to of in the encouraging which not fact sales this inquiries this but the absence orders the
the sorting for BACS technology which in Our activated X-Mini cell second proprietary short. kit buoyancy quarter based or we our launched on is
cell-based bottom. opposed and researchers allows using X-Mini X-Mini products developing technology with technology. Through isolate from cell to traditional using the target top type subsidiary development to their surface on bubble our cells experiment said is These subsets of bind The enabling sink of reagents specifically As to such complex to the themselves familiarize centrifugation, as the a micro bind single a shelf float the isolates MACS and cells using a and antibodies cell to BACS reminder blood target blood them from a BACS to as employs cells therapies. microscopic kits host to mixture laboratory off other cell the and targeted is liquid for the blood to equipment. of standard several specific market the of research ThermoGenesis Cesca's desired bubbles type. non-target CAR-T device bubbles and micro first while
for kit population first isolation select population for cells to The CDX+ of PBMCs. the the which users selection have primary X-Mini from peripheral T-cells allow mononuclear is cell To any a a the designed antibody. to provide of blood starting or flexibility they
materials CDX successfully on to distributors are look journal do kits to control publication will to improved CDX. potential moving the Hill, those aim have under completed will We that be feedback on, we X the series the we to and of an -- with CDXX, now of efficiencies schedule Carolina, We cell because which with UNC evaluation seeing Before want to results not the and and them CDX+ hopefully forward note the the in published UNC technology upcoming evaluation, don't agreement of manufacturing any think provide different received UNC University we our we that results such of That quarter. of demo demo and quarter. our We launch develop Chapel by T-cells evaluation North with I announced this kits valuable the are market last will several during on be our do until that types as said, highly potential publishes to not day their planning team results. encouraged second transferred customers from updates their our we beyond the address and providing technology based X-Mini
will initial and quarter closed the moving of reflected of in subsequent results. third Now the end to second commercial systems on, X-LAB our and our therefore be X-Wash quarter sales
therapy these had This instead it beginning, first sales are product are encouraging sales first that mouth of that activity these tires ago, occurred word via moment a our value and the direct as kick to formal at conferences. first coming despite of our is a collaborators opportunity lack alluded right are and I to As just were customers those conferences products and after seems potential sales because cell our notable key the the they of resonating. exhibitions force
downloaded recently and is optimization established in innovation" entitled a Officer, the Phil Technology we are upon leader have CAR-T as than were Coelho, view That manufacturer field another being the told we and the gene article said, April cell Phil insights we in diligently aside, other this generated. an time edition therapy more momentum in any an the technology appeared article is As Chief of that by to indication build that publication. our we was which awareness the to-date. of "Driving authored through working
for advanced be facilities to additional clinical the and located. leading CAR-T of and their happen say sciences technology, pleased global sites manufacturing of of developers laboratory to wherever we products series flexible X meet that am the so are partner can trial that to we distributor products, needs As prepare in we release be life a I or discussions with commercial
complex range nature therapy fact and each of and availability barriers dose. contributes partners Also limits Therapeutics pursuing improving more high As these ability to costs, in platform or developers manufacturing in cell same CAR-TXpress are more designed support time and one engage process automation actively CAR-TXpress at the further with to significantly help per opening scale, to lower modular widespread faster drug industry the new this high therefore, With It's cost drugs consistency. these key of more repeating development to from time of fair to we can capacity, Cecsa's to to immunotherapies. needs a manufacturing $XXX,XXX allow Chris stand cost, the extremely highly leading in manufacture that to significant researchers or to their remarks, low $XXX,XXX mentioned manufacture CAR-T automate personalized the this his is are one at yields steps mind, while to the and and and plan which project.
provide of this as current and the point, the we CDMO the territories important our of for blood storage products on blood and we China-based setting in development work progressing U.S. include care of with AXP this cellular in to contract value centers higher market. number currently China in growing last as manufacturing CDMO of of portfolio as stem a legacy we autologous in products, cord CAR-T only CDMO with and brief IncoCell bone us quarter's and PXP the hematopoietic services agreement short I'd and key collection to overview terms concentrates clinical As the key discussed including a processing I'm IncoCell a second And large is for positions clinics. through additional long-term collaborations of cells planned agreement for At that and the this call, a we exclusive in expanded with trials is pleased our from pursuing beginning of as product cryogenic Limited. view of our that year, which are surgical storage our archive peripheral derived for cell underway. marrow the license bio player other including Tianjin say and into to to success. like point or March U.S. isolation
cultures offering strategy a that on X-Mini market, product our only. employs semi-automated moment focused growth includes take just volume use marrow functionally as which washes the or our is cells to CAR-T and X-Mini addition our rapid with different Series portfolio the washing research of I'll closed a sources an to cells of for a including immunotherapy of given flexibility within as solutions well highlight needs reduces In isolation researchers as the products. X magnetic kits through capabilities isolation. samples, isolate separates bubbles for meet experiment CAR-T X-WASH buoyancy leukopheresis broader X-WASH Cecso to target micro from and programmable to blood micro These broad reformulation; bubbles CDMO target industry beads activated for aspirates coupled the constituents many sorting. cells This X-LAB cells bone system with is with provide the allow X-LAB cell cell separation. frozen alternative for to ecosystem. and volume. to ficoll-free the
have potential forward providing noted on As on our look to call, early been calls. quarter's partners we and more discussions last future with productive specifics
position field. us made recent I our Jeff CAR-TXpress most months introduction the proud review high a are market among to the are handsfree pioneer transformative We of for development PXP therapeutics recent up the that of financials. processing with are of of the with Cecsa in top-tier products automated believe highest that, the And let continuation we recovery progress operation, commercialization that for Jeff? both the portfolio advantages including call and in and in the The a for remains have closing, for rates sets technologies of a that year over ahead. the reflect me and distinct detailed and more bioprocessing In cell-based a volume industry. turn providing in
